您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Tenofovir Disoproxil Fumarate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tenofovir Disoproxil Fumarate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tenofovir Disoproxil Fumarate图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
25mg电议
100mg电议

产品介绍
富马酸替诺福韦酯是一种核苷酸逆转录酶抑制剂,用于治疗 HIV 和慢性乙型肝炎。

Cell lines

MT-2 cells and PBMCs

Preparation method

The solubility of this compound in DMSO is >31.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

0.007 μM or 0.005 μM

Applications

In MT-2 cells and PBMCs, Tenofovir Disoproxil Fumarate inhibited HIV replication with the EC50 values of 0.007 μM and 0.005 μM, respectively. The anti-HIV activity of Tenofovir Disoproxil Fumarate was shown to be 36- to 90-fold greater than that of Tenofovir.

产品描述

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor that inhibits the replication of human immunodeficiency virus (HIV) in MT-2 cells and PBMC with the half maximal effective concentration EC50 values of 0.007 μmol/L and 0.005 μmol/L [1].

Shortly upon administration, tenofovir disoproxil fumarate rapidly goes through esterase hydrolysis removing the two ester groups and yielding tenofovir, which is a nucleotide analogue with anti-viral activity against retroviruses including HIV-1, HIV-2 and hepadnaviruses. Tenofovir is phosphorylated by cellular nucleotide kinase and adenylate kinase and eventually converted into its active anabolite tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase and terminates the growing DNA chain [2].

References:
[1] Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002 Oct;24(10):1515-48.
[2] Brian P. Kearney, John F. Flaherty, Jaymin Shah. Tenofovir Disoproxil Fumarate. Clinical Pharmacokinetics. August 2004, Volume 43, Issue 9, pp 595-612